Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.50 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | SUV39H2 | Q9H5I1 | 9/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30897180 | 0.95 | CKS1B (0.50) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL31262679 | 0.86 | JAK3 (0.49) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL31262459 | 0.86 | JAK3 (0.49) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL2422222 | 0.85 | PIM1 (0.52) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL15100929 | 0.85 | PIM1 (0.52) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL2422225 | 0.85 | PIM1 (0.52) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL22976834 | 0.85 | BTK (0.51) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL22976836 | 0.85 | BTK (0.51) | PIM1PIM3PIM2JAK3BTK | |
| SCHEMBL22976465 | 0.85 | CHRM4 (0.42) | — | |
| SCHEMBL22976467 | 0.85 | CHRM4 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2025-05-01 | — | — | US | disclosed |
| EP-4294797-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | Crinetics Pharmaceuticals, Inc. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | Crinetics Pharmaceuticals, Inc. (US) | 2022-10-25 | — | — | US | disclosed |
| WO-2022177974-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220259175-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | Crinetics Pharmaceuticals, Inc. | 2022-08-18 | — | — | US | disclosed |
| EP-4013748-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144802-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | PIM1 3779/4885PIM3 3327/4885PIM2 3895/4885 |
| US-11479540-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, SSTR3 | PIM1 3779/4885PIM3 3327/4885PIM2 3895/4885 |
| US-20220259175-A1 | CRYSTALLINE FORMS OF A SOMATOSTATIN MODULATOR | SSTR5, SSTR3, SSTR4 | PIM1 4083/4885PIM3 3994/4885PIM2 4245/4885 |
| US-20250136573-A1 | NONPEPTIDE SOMATOSTATIN TYPE 5 RECEPTOR AGONISTS AND USES THEREOF | SSTR5, SSTR4, SSTR3 | PIM1 3779/4885PIM3 3327/4885PIM2 3895/4885 |
| US-11773076-B2 | Crystalline forms of a somatostatin modulator | SSTR5, SSTR3, SSTR4 | PIM1 4083/4885PIM3 3994/4885PIM2 4245/4885 |
| US-12600709-B2 | Nonpeptide somatostatin type 5 receptor agonists and uses thereof | SSTR5, SSTR4, GLP1R | PIM1 1241/4885PIM3 1002/4885PIM2 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.